Stocks and Investing
Stocks and Investing
Thu, November 14, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, November 13, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Madhu Kumar Maintained (ARWR) at Strong Buy with Increased Target to $59 on, Nov 13th, 2019
Madhu Kumar of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $46 to $59 on, Nov 13th, 2019.
Madhu has made no other calls on ARWR in the last 4 months.
There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 1 agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Joel Beatty of "Baird" Downgraded from Buy to Hold and Held Target at $39 on, Thursday, October 24th, 2019
This is the rating of the analyst that currently disagrees with Madhu
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $45 on, Tuesday, October 22nd, 2019
Contributing Sources